Key Highlights

  • Two years: the term of the master maintenance and services agreement MindWave, a unit of Apimeds Pharmaceuticals (NYSEAMERICAN:APUS), signed with Delaware-based BlockAssure on October 5, 2026, renewing for one-year periods unless either side gives 90 days' notice.
  • 20 percent of AssureCoin: the allocation MindWave earns on top of service fees, Fully Vested on delivery, with anti-dilution terms that hold its share if more tokens are issued during the term or for two years afterward.
  • About 44 percent: Apimeds (NYSEAMERICAN:APUS) closed near USD 4.65 on Monday, on Volume more than ten times its 100-day average of 2.06 million shares, after trading up about 77 percent in premarket, per published market data.
  • September 14, 2026: the effective date of an earlier 12-month MindWave agreement with Singapore-based AQUAE Holdings, which pays a separate allocation equal to 20 percent of ALCI Credits issued on that network, a different digital asset from AssureCoin.

What MindWave Will Build

MindWave Innovations Inc. USA, a Wholly Owned Subsidiary of Apimeds, will develop, audit, deploy and operate AssureChain, a dedicated subnet of its MindChain network that runs BlockAssure's insurance and Reinsurance functions on-chain and anchors to Ethereum. MindWave is BlockAssure's exclusive blockchain provider during the term. Each module will be security-audited before production, and personal data will not be written on-chain except in hashed or tokenized form. The agreement took effect in October 2026.

How MindWave Gets Paid

Consideration combines software development and technology service fees with an allocation equal to 20 percent of the total Supply of AssureCoin, a digital token BlockAssure plans to create. The allocation vests fully on delivery. Some coverage of the deal mixes this term with the AQUAE agreement, where the 20 percent applies to ALCI Credits instead. A September 29, 2026 agreement with Flash Sports & Media Holdings adds a third blockchain services contract to MindWave's recent pipeline.

A Pharma Name With a New Business

A token allocation is only worth what the market pays for a token that does not yet exist. Apimeds' name still points to pharmaceuticals, yet its board approved non-binding plans in March 2026 to expand into Korean cosmetics and a photo booth platform. The stock rose about 44 percent on heavy volume, so optimism may already be priced in. The evidence to watch is audited Revenue from MindWave rather than token valuations or contract headlines.

Where Things Stand

The jump reflects a Business pivot being priced ahead of its financials. Apimeds (NYSEAMERICAN:APUS) now has three blockchain services contracts in about three weeks, but payment includes tokens that have yet to launch, and the company's core identity remains unclear after its cosmetics and photo booth plans. Volume more than ten times average suggests speculative trading. Next catalysts are the first fee revenue from MindWave, the launch of AssureCoin and the third quarter results, none of which has a confirmed date. Revenue and cash disclosures will show whether the pivot is more than contracts.